Negative in Ames, CHO chromosome aberration and rat in vivo micronucleus assays
“Centanafadine was negative in a valid, full battery of genetic toxicology assays including a reverse bacterial mutagenicity (Ames) assay, a chromosome aberration assay (CHO cells), and a rat in vivo micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Carcinogenicity
6-month transgenic mouse and 2-year rat: no drug-related neoplasms
“Centanafadine was adequately evaluated in a 6-month transgenic mouse carcinogenicity study and a 2-year rat carcinogenicity study. There was no evidence of drug-related neoplasms in either study.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat fertility, rat and rabbit EFD, rat PPND and rat juvenile studies conducted
“Reproductive and developmental toxicity studies that were conducted included fertility studies in male and female rats, embryofetal development (EFD) studies in rats and rabbits, a pre- and post-natal development (PPND) study in rats, and a juvenile animal study (JAS) in rats.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗
Safety pharmacology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Genotox: Ames
Negative
“Centanafadine was negative in a valid, full battery of genetic toxicology assays including a reverse bacterial mutagenicity (Ames) assay, a chromosome aberration assay (CHO cells), and a rat in vivo micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Genotox: in vitro mammalian
Negative chromosome aberration assay in CHO cells
“Centanafadine was negative in a valid, full battery of genetic toxicology assays including a reverse bacterial mutagenicity (Ames) assay, a chromosome aberration assay (CHO cells), and a rat in vivo micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Genotox: in vivo
Negative rat in vivo micronucleus assay
“Centanafadine was negative in a valid, full battery of genetic toxicology assays including a reverse bacterial mutagenicity (Ames) assay, a chromosome aberration assay (CHO cells), and a rat in vivo micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Carcinogenicity model
6-month transgenic mouse and 2-year rat; no drug-related neoplasms
“Centanafadine was adequately evaluated in a 6-month transgenic mouse carcinogenicity study and a 2-year rat carcinogenicity study. There was no evidence of drug-related neoplasms in either study.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Carcinogenicity timing
Rat and mouse carcinogenicity studies completed and submitted with the NDA
“In this submission the sponsor included reports of two animal carcinogenicity studies, one in rats and one in mice.”
✓ VerifiedFDA multi-discipline review, p. 313Source ↗
hERG / QT
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative